Potentially Resectable MET-altered Non-Small Cell Lung Cancer
1 clinical trials · Condition
◉ Watch Potentially Resectable MET-altered Non-Small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) (NCT06644313) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-11-01 |
Track Potentially Resectable MET-altered Non-Small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.